• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    61 Biggest Movers From Yesterday

    4/28/22 4:17:36 AM ET
    $AFIB
    $AGRX
    $ALKS
    $APCX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFIB alert in real time by email

    Gainers

    • Vivakor, Inc. (NASDAQ:VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of up to $250 million.
    • Acutus Medical, Inc. (NASDAQ:AFIB) gained 36% to settle at $1.09 after the company announced agreements to fund strategic growth priorities.
    • Locafy Limited (NASDAQ:LCFY) jumped 34.2% to close at $1.57.
    • Cosmos Holdings Inc. (NASDAQ:COSM) shares gained 34% to close at $1.42 after jumping over 16% on Tuesday. Cosmos Holdings recently posted FY21 adjusted net income of $384K.
    • Tempest Therapeutics, Inc. (NASDAQ:TPST) surged 30.1% to close at $3.07. Tempest reported a $15 million private placement financing.
    • Studio City International Holdings Limited (NYSE:MSC) gained 29.7% to close at $5.45.
    • Canterbury Park Holding Corporation (NASDAQ:CPHC) surged 22.2% to settle at $32.92. Canterbury Park, last month, reported fourth-quarter FY21 sales growth of 128% year-on-year, to $13.95 million.
    • Bon Natural Life Limited (NASDAQ:BON) gained 18.5% to close at $4.54. Bon Natural Life recently announced plans to launch new multi-functional health supplements.
    • Elevation Oncology, Inc. (NASDAQ:ELEV) jumped 17.8% to close at $2.84.
    • PAVmed Inc. (NASDAQ:PAVM) gained 16.5% to settle at $1.27.
    • AppTech Payments Corp. (NASDAQ:APCX) gained 15.9% to settle at $1.68.
    • Chindata Group Holdings Limited (NASDAQ:CD) surged 15.3% to close at $5.79.
    • Medigus Ltd. (NASDAQ:MDGS) gained 15.2% to close at $1.0783. Medigus' ParaZero recently signed an agreement to develop custom safety solution for a leading global automotive manufacturer's drone program.
    • TradeUP Global Corporation (NASDAQ:TUGC) climbed 15.1% to settle at $10.59.
    • Atossa Therapeutics, Inc. (NASDAQ:ATOS) gained 15% to close at $1.11. Atossa Therapeutics recently announced completion of Part B of clinical study of AT-H201.
    • Direct Digital Holdings, Inc. (NASDAQ:DRCT) gained 15% to close at $2.53.
    • Alliance Resource Partners, L.P. (NASDAQ:ARLP) jumped 14.9% to close at $18.16. Alliance Resource Partners sees net income of $0.27-$0.28 per basic and diluted limited partner unit for 2022 quarter.
    • Nutex Health, Inc. (NASDAQ:NUTX) rose 13.5% to close at $8.72 after jumping 74% on Tuesday.
    • Nordic American Tankers Limited (NYSE:NAT) climbed 12.9% to settle at $2.88.
    • Ardmore Shipping Corporation (NYSE:ASC) gained 12.8% to close at $6.33.
    • Alkermes plc (NASDAQ:ALKS) rose 11.9% to close at $30.38 following better-than-expected Q1 results.
    • Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) gained 11.8% to close at $24.41. Pfizer agreed to invest $25 million in Zentalis Pharmaceuticals via the purchase of 953,834 shares at $26.21 per share.
    • Vertiv Holdings Co (NYSE:VRT) rose 11.5% to close at $12.87 following upbeat Q1 results.
    • Mattel, Inc. (NASDAQ:MAT) gained 10.8% to close at $24.49 following a WSJ report suggesting the company is in talks with private-equity firms about a potential sale.
    • Repligen Corporation (NASDAQ:RGEN) shares jumped 10.5% to close at $157.51 after reporting upbeat Q1 results.
    • JinkoSolar Holding Co., Ltd. (NYSE:JKS) gained 9.7% to close at $55.09.
    • Digital World Acquisition Corp. (NASDAQ:DWAC) rose 9.2% to close at $44.55.
    • Bilibili Inc. (NASDAQ:BILI) gained 8.1% to close at $22.23.
    • Enphase Energy, Inc. (NASDAQ:ENPH) gained 7.7% to close at $165.71 after the company reported better-than-expected Q1 adjusted EPS and sales results and issued Q2 sales guidance above analyst estimates.
    • Visa Inc. (NYSE:V) rose 6.5% to close at $214.11 following upbeat quarterly earnings.
    • Microsoft Corporation (NASDAQ:MSFT) rose 4.8% to close at $283.22 as the company reported better-than-expected results for its third quarter.


    Losers

    • JE Cleantech Holdings Limited (NASDAQ:JCSE) dipped 68.4% to close at $5.12 on Wednesday.
    • Molecular Partners AG (NASDAQ:MOLN) shares fell 36.9% to close at $8.70. The company’s collaborating partner Amgen for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review.
    • Agile Therapeutics, Inc. (NASDAQ:AGRX) dipped 29.9% to settle at $3.14 following effectiveness of 1:40 reverse stock split.
    • Q&K International Group Limited (NASDAQ:QK) shares fell 25.4% to close at $0.88 after jumping around 19% on Tuesday.
    • Silence Therapeutics plc (NASDAQ:SLN) fell 23.6% to settle at $11.07.
    • NCR Corporation (NYSE:NCR) fell 23.2% to close at $28.67 after the company reported worse-than-expected Q1 EPS and sales results. The company also cut its FY22 EPS and sales guidance.
    • Evoke Pharma, Inc. (NASDAQ:EVOK) fell 23.2% to close at $0.66. Evoke Pharma shares jumped over 118% on Tuesday as the FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis in adults.
    • Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) dipped 22.8% to close at $0.21. Salarius Pharmaceuticals recently announced a $2.3 million registered direct offering.
    • Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) fell 19.7% to close at $10.44. Rani Therapeutics, last month, posted a Q4 loss of $0.27 per share.
    • Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) fell 18.4% to close at $5.80. Diffusion Pharmaceuticals recently company announced a 1-for-50 reverse stock split.
    • Forge Global Holdings, Inc. (NYSE:FRGE) fell 18% to close at $15.13.
    • Solid Biosciences Inc. (NASDAQ:SLDB) dipped 17% to close at $0.6434. Solid Biosciences is shaving down its pipeline, updating its operations strategy to prioritize the advancement of AAV-mediated gene transfer therapies, SGT-001 and SGT-003.
    • iSpecimen Inc. (NASDAQ:ISPC) dropped 16.9% to close at $3.19.
    • Extreme Networks, Inc. (NASDAQ:EXTR) fell 16.8% to close at $9.40 following Q3 results.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) dipped 16.6% to settle at $12.10. ToughBuilt Industries reported a 41% online sales growth through Amazon in Q1.
    • Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) dropped 16.5% to close at $0.9101. Citius Pharmaceuticals enrolled first patient in Phase 2b study of Halo-lido for the prescription treatment of haemorrhoids.
    • Sono Group N.V. (NASDAQ:SEV) fell 16.4% to close at $4.93 after the company reported a 10 million share follow-on offering.
    • IDEX Biometrics ASA (NASDAQ:IDBA) dipped 15.7% to close at $10.98.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) fell 14.9% to settle at $0.3697.
    • ION Geophysical Corporation (NYSE:IO) declined 14.7% to close at $0.4945. Alliance Global Partners downgraded the stock from Buy to Sell.
    • Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) dropped 14.6% to close at $0.7670.
    • F5, Inc. (NASDAQ:FFIV) fell 12.8% to close at $169.01 after the company reported Q2 earnings results and issued Q3 sales guidance below analyst estimates.
    • Spotify Technology S.A. (NYSE:SPOT) dipped 12.4% to settle at $96.67 after the company reported Q1 financial results.
    • Bright Minds Biosciences Inc. (NASDAQ:DRUG) fell 9.4% to close at $1.06.
    • Diebold Nixdorf, Incorporated (NYSE:DBD) dropped 8.5% to close at $4.32.
    • Hawaiian Holdings, Inc. (NASDAQ:HA) dropped 8.2% to close at $17.04 following Q1 results.
    • Trinity Industries, Inc. (NYSE:TRN) fell 8.1% to close at $28.15 following downbeat quarterly results.
    • Deutsche Bank Aktiengesellschaft (NYSE:DB) shares fell 6.9% to close at $10.13 following Q1 earnings.
    • Capital One Financial Corporation (NYSE:COF) fell 6% to settle at $124.35 after the company reported Q1 earnings results.
    • Alphabet Inc. (NASDAQ:GOOGL) fell 3.7% to close at $2,285.89 following downbeat quarterly earnings.
    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB
    $AGRX
    $ALKS
    $APCX

    CompanyDatePrice TargetRatingAnalyst
    Visa Inc.
    $V
    4/22/2026$365.00Outperform
    BMO Capital Markets
    Nordic American Tankers Limited
    $NAT
    4/22/2026$4.50In-line → Underperform
    Evercore ISI
    Microsoft Corporation
    $MSFT
    4/21/2026$635.00 → $600.00Buy
    Citigroup
    Alphabet Inc.
    $GOOGL
    4/20/2026$370.00 → $380.00Overweight
    KeyBanc Capital Markets
    Deutsche Bank AG
    $DB
    4/20/2026Overweight → Equal Weight
    Barclays
    Repligen Corporation
    $RGEN
    4/17/2026$160.00Buy
    Rothschild & Co Redburn
    Microsoft Corporation
    $MSFT
    4/15/2026$540.00 → $500.00Outperform
    Robert W. Baird
    Microsoft Corporation
    $MSFT
    4/14/2026$620.00 → $515.00Outperform
    Mizuho
    More analyst ratings

    $AFIB
    $AGRX
    $ALKS
    $APCX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $ALKS
    $APCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets initiated coverage on Visa with a new price target

    BMO Capital Markets initiated coverage of Visa with a rating of Outperform and set a new price target of $365.00

    4/22/26 7:58:45 AM ET
    $V
    Real Estate

    Nordic American Tanker downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Nordic American Tanker from In-line to Underperform and set a new price target of $4.50

    4/22/26 7:53:45 AM ET
    $NAT
    Marine Transportation
    Consumer Discretionary

    Citigroup reiterated coverage on Microsoft with a new price target

    Citigroup reiterated coverage of Microsoft with a rating of Buy and set a new price target of $600.00 from $635.00 previously

    4/21/26 6:45:24 AM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    $AFIB
    $AGRX
    $ALKS
    $APCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    Chief Executive Officer Derosa Thomas Joseph bought $3,299 worth of shares (10,000 units at $0.33), increasing direct ownership by 22% to 56,096 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    3/5/26 4:58:08 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Director Lord Albert L bought $9,578 worth of shares (29,606 units at $0.32), increasing direct ownership by 0.91% to 3,300,000 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    3/5/26 4:57:43 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    $AFIB
    $AGRX
    $ALKS
    $APCX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Canterbury Park Holding Corporation 'New'

    DEFA14A - Canterbury Park Holding Corp (0001672909) (Filer)

    4/24/26 11:00:53 AM ET
    $CPHC
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form DEF 14A filed by Canterbury Park Holding Corporation 'New'

    DEF 14A - Canterbury Park Holding Corp (0001672909) (Filer)

    4/24/26 11:00:24 AM ET
    $CPHC
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 424B5 filed by Citius Pharmaceuticals Inc.

    424B5 - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

    4/24/26 9:24:38 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $ALKS
    $APCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock

    NEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder. The gross proceeds from the offering, before deducting underwriting discount

    4/24/26 10:23:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

    CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 5,076,143 shares of its common stock  (or pre-funded warrants in lieu thereof) at a purchase price of $0.985 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,076,143 shares of comm

    4/24/26 8:00:00 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of American Tungsten & Antimony Limited

    Deutsche Bank announced today its appointment as depositary bank for the American Depositary Receipt program of American Tungsten & Antimony Limited. American Tungsten & Antimony Limited (OTC:ATAYY) is an ASX-listed critical minerals company ((ASX: AT4, OTCQB:ATALF) focused on the exploration and development of antimony and tungsten projects in the United States. The company's portfolio includes the flagship Antimony Canyon Project in Utah, together with a portfolio of tungsten projects across Utah and Nevada including Tennessee Mountain, Fraction Lode, Nightingale and Dutch Mountain. The company is pursuing a U.S.-based hub-and-spoke processing and refining strategy aligned with U.S. Gov

    4/23/26 4:05:00 PM ET
    $DB
    Major Banks
    Finance

    $AFIB
    $AGRX
    $ALKS
    $APCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Reed Michael Lee

    4 - Nutex Health Inc. (0001479681) (Issuer)

    4/24/26 2:35:38 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Director Saunders Scott J

    4 - Nutex Health Inc. (0001479681) (Issuer)

    4/24/26 2:32:08 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Director Jaumot Frank E

    4 - Nutex Health Inc. (0001479681) (Issuer)

    4/24/26 2:27:51 PM ET
    $NUTX
    Real Estate

    $AFIB
    $AGRX
    $ALKS
    $APCX
    Leadership Updates

    Live Leadership Updates

    View All

    Visa Launches Validator Node on Tempo Blockchain

    Visa has joined the Tempo network as an anchor validator, supporting transaction validation and accelerating the development of onchain payment infrastructure. Visa (NYSE:V), a global leader in digital payments, today announced it has officially launched its validator node on the Tempo network, marking a key milestone in Visa's continued advancement of blockchain infrastructure leadership and its role in shaping stablecoin payments. The launch underscores Visa's commitment to running critical blockchain operations in-house and strengthening the foundations of onchain payment innovation. Tempo, the next generation blockchain built for agentic commerce and real-time payments, has expanded

    4/14/26 9:06:00 AM ET
    $V
    Real Estate

    Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

    Adds dedicated business development leadership to support Tempest's strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest's global business development efforts, including strategic partners

    4/14/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

    SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Dr. Sara Kenkare-Mitra as a Strategic Advisor. Dr. Kenkare-Mitra brings nearly three decades of experience in biologics and small molecule drug discovery and development, with a proven track record of global regulatory approvals and commercial launches across oncology, immunology, neurodegeneration, ophthalmology, and respiratory diseases. "Sara is a highly accomplished leader and respected drug developer, and we are thrilled to we

    4/9/26 7:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $ALKS
    $APCX
    Financials

    Live finance-specific insights

    View All

    Direct Digital Holdings Announces Reverse Stock Split

    HOUSTON, April 23, 2026 /PRNewswire/ -- Direct Digital Holdings, Inc. (NASDAQ:DRCT) ("Direct Digital Holdings" or the "Company"), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC ("Colossus SSP") and Orange 142, LLC ("Orange 142"), today announced a 4-to-1 reverse stock split of all classes of its common stock. The Company expects the Class A common stock to begin trading on a split-adjusted basis on The Nasdaq Stock Market as of the commencement of trading on April 27, 2026. The reverse stock split is intended to allow the Company to maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.As previously ann

    4/23/26 8:30:00 AM ET
    $DRCT
    Advertising
    Consumer Discretionary

    Nutex Health Schedules 2026 First Quarter Financial Results Release and Conference Call

    HOUSTON, April 22, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Form 10-Q for the first fiscal quarter ended March 31, 2026, on Thursday, April 30, 2026 after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, May 1, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and provide a b

    4/22/26 4:15:00 PM ET
    $NUTX
    Real Estate

    Repligen to Report First Quarter 2026 Financial Results

    WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. The w

    4/22/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFIB
    $AGRX
    $ALKS
    $APCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

    SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

    11/27/24 4:05:31 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Direct Digital Holdings Inc.

    SC 13D/A - Direct Digital Holdings, Inc. (0001880613) (Subject)

    11/22/24 4:11:23 PM ET
    $DRCT
    Advertising
    Consumer Discretionary